視網膜疾病治療市場－全球產業規模、佔有率、趨勢、機會和預測，按類型、劑型、配銷通路、地區和競爭細分，2020-2030 年

2024 年全球視網膜疾病治療市場價值為 150.2 億美元，預計到 2030 年將達到 256 億美元，複合年成長率為 9.25%。

全球視網膜疾病治療市場正進入關鍵的轉型期，受人口結構變化、全球疾病發生率上升以及精準醫療和再生療法創新浪潮的推動。老年黃斑部病變 (AMD)、糖尿病視網膜病變 (DR)、視網膜靜脈阻塞 (RVO) 和視網膜色素變性等疾病仍然是高負擔、危及視力的疾病，存在大量未滿足的臨床需求。不斷成長的患者群體以及先進生物製劑、基因標靶療法和長效給藥系統的日益普及正在推動這一持續的市場擴張，這些系統正在重塑臨床治療方案。與以往主要關注病情穩定的時代不同，目前的市場軌跡反映了向恢復性療效的轉變，越來越重視神經再生、視功能恢復和治療反應的持久性。

關鍵市場促進因素

視網膜疾病盛行率上升

主要市場挑戰

治療費用高昂，負擔能力有限

主要市場趨勢

轉向長效和緩釋療法

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：視網膜疾病治療市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依類型（黃斑部病變、糖尿病視網膜病變、其他）
  • 按劑型（凝膠、眼藥水、膠囊及藥片、眼藥水、藥膏）
  • 按配銷通路（醫院藥房、網路藥房、零售藥房）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美視網膜疾病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲視網膜疾病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第8章：亞太視網膜疾病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美洲視網膜疾病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東與非洲視網膜疾病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 13 章：全球視網膜疾病治療市場：SWOT 分析

第 14 章：競爭格局

• Santen Pharmaceutical Co., Ltd.
• Regeneron Pharmaceuticals Inc.
• Graybug Vision, Inc.
• Shire plc (Takeda Pharmaceutical Company Limited)
• Bayer AG
• AbbVie Inc.
• Genentech (F. Hoffmann-La Roche Ltd)
• Kubota Vision Inc.
• Pfizer, Inc.
• Bausch + Lomb

第 15 章：策略建議

第16章調查會社について,免責事項

Global Retinal Disorder Treatment market was valued at USD 15.02 Billion in 2024 and is expected to reach USD 25.60 Billion by 2030 with a CAGR of 9.25%.

The Global Retinal Disorder Treatment Market is entering a pivotal phase of transformation, propelled by demographic shifts, rising global disease incidence, and a wave of innovation in precision and regenerative therapeutics. Conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal vein occlusion (RVO), and retinitis pigmentosa continue to represent high-burden, sight-threatening disorders with considerable unmet clinical need. This sustained market expansion is being fueled by a growing patient base and increased adoption of advanced biologics, gene-targeted therapies, and long-acting drug delivery systems that are reshaping clinical treatment protocols. Unlike previous eras focused primarily on disease stabilization, the current market trajectory reflects a transition toward restorative outcomes, with a growing emphasis on neural regeneration, visual function recovery, and durability of therapeutic response.

Key Market Drivers

Rising Prevalence of Retinal Disorders

The increasing prevalence of retinal disorders is a fundamental factor fueling the expansion of the Global Retinal Disorder Treatment Market. Globally, over 2.2 billion people are affected by near or distance vision impairment. Notably, in at least 1 billion of these cases, the impairment was either preventable or remains untreated highlighting a significant unmet need and an addressable market opportunity for eye care solutions. Conditions such as age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and retinitis pigmentosa are becoming increasingly common across global populations. The global burden of age-related macular degeneration (AMD) is on a sharp upward trajectory, driven by demographic aging. Prevalence reached approximately 196 million cases in 2020 and is forecasted to rise to 288 million by 2040 representing a 47% increase over two decades and signaling a growing demand for targeted retinal therapies and long-term disease management solutions.

Diabetic retinopathy remains one of the most common complications of diabetes. According to the International Diabetes Federation, over 530 million people are living with diabetes worldwide, a number projected to rise sharply in the coming decades. Between 1990 and 2022, the global diabetic population grew more than fourfold from 200 million to 830 million underscoring a dramatic escalation in metabolic health challenges. In 2021 alone, diabetes and diabetes-related kidney disease accounted for over 2 million deaths. Additionally, elevated blood glucose levels were responsible for approximately 11% of all cardiovascular-related fatalities, reinforcing the urgent need for integrated diagnostic, therapeutic, and monitoring solutions across the healthcare value chain. Poor dietary habits, lack of physical activity, and high rates of smoking and obesity are increasing the risk factors for retinal disorders in both developed and developing countries. This expanding patient population directly translates into higher demand for ongoing treatment and management solutions, thereby driving market growth.

Many retinal disorders are chronic and progressive, requiring long-term or lifelong treatment. For instance, patients diagnosed with wet AMD typically undergo regular intravitreal injections of anti-VEGF agents. This recurrent treatment model generates sustained revenue streams for pharmaceutical companies and significantly contributes to market scalability. Additionally, the long-term nature of retinal diseases encourages investment in patient monitoring, follow-up diagnostics, and personalized therapies, creating commercial opportunities across various segments of the treatment ecosystem. Untreated or poorly managed retinal disorders can lead to severe vision impairment or blindness, resulting in reduced quality of life, productivity losses, and increased caregiver burden.

This economic and social impact has prompted governments and healthcare providers to allocate more resources to preventive care, early detection, and timely treatment. As a result, there is increased public and private investment in eye health infrastructure, awareness campaigns, and affordable access to retinal care further accelerating market expansion. The rising prevalence of retinal disorders incentivizes pharmaceutical, biotech, and medical device companies to expand their treatment portfolios. This includes developing novel therapeutics such as: Long-acting anti-VEGF agents, Gene therapies and cell-based interventions, Sustained-release drug delivery systems. This diversification meets the varied needs of a growing and heterogeneous patient population, supporting deeper market penetration and broader product adoption.

Key Market Challenges

High Cost of Treatment and Limited Affordability

Retinal disorder treatments particularly anti-VEGF therapies, advanced diagnostics (like Optical Coherence Tomography), and retinal surgeries are often prohibitively expensive, especially in low- and middle-income markets. The recurring nature of treatment (e.g., monthly injections for wet AMD) further compounds financial burden on patients.

This cost barrier significantly limits market penetration in price-sensitive regions. Even in developed economies, budget constraints in public health systems and restricted reimbursement policies pose challenges for long-term patient adherence. For industry stakeholders, Reduced patient retention and compliance, Pricing pressure from governments and insurance providers, Limited scalability of premium therapies in emerging markets. To achieve sustained growth, companies need to invest in cost-effective delivery models, biosimilars, and pricing strategies tailored to diverse economic segments.

Key Market Trends

Shift Toward Long-Acting and Sustained-Release Therapies

One of the most transformative developments in retinal care is the industry-wide move toward long-acting formulations and sustained-release drug delivery systems. Traditional treatments such as monthly intravitreal injections for wet AMD have been effective but come with challenges related to patient compliance, clinical burden, and healthcare costs. Port delivery systems (e.g., Genentech's Susvimo), Extended-duration anti-VEGF agents (e.g., Vabysmo, Eylea HD), Biodegradable implants and micro-pumps under clinical development.

This trend enhances patient adherence, reduces the frequency of clinic visits, and improves overall treatment outcomes critical factors for long-term market growth. For pharmaceutical and biotech companies, it opens opportunities to: Differentiate their offerings with more convenient and premium solutions, Command pricing premiums for innovation. Capture broader patient segments, especially those currently under-treated due to procedural fatigue or logistical barrier. As the market continues to shift toward durability and patient-centric delivery, players that invest in sustained-release platforms are expected to gain a competitive edge.

Key Market Players

• Santen Pharmaceutical Co., Ltd.
• Regeneron Pharmaceuticals Inc.
• Graybug Vision, Inc.
• Shire plc (Takeda Pharmaceutical Company Limited)
• Bayer AG
• AbbVie Inc.
• Genentech (F. Hoffmann-La Roche Ltd)
• Kubota Vision Inc.
• Pfizer, Inc.
• Bausch + Lomb

Report Scope:

In this report, the Global Retinal Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Retinal Disorder Treatment Market, By Product:

• Macular Degeneration
• Diabetic Retinopathy
• Others

Retinal Disorder Treatment Market, By Dosage Form:

• Gels
• Eye Solutions
• Capsules & Tablets
• Eye Drops
• Ointments

Retinal Disorder Treatment Market, By Distribution Channel:

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Retinal Disorder Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Retinal Disorder Treatment Market.

Available Customizations:

Global Retinal Disorder Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Retinal Disorder Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Macular Degeneration, Diabetic Retinopathy, Others)
  • 5.2.2. By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Retinal Disorder Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Dosage Form
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Retinal Disorder Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Dosage Form
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Retinal Disorder Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Dosage Form
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Retinal Disorder Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Dosage Form
      • 6.3.3.2.3. By Distribution Channel

7. Europe Retinal Disorder Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Dosage Form
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Retinal Disorder Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Dosage Form
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom Retinal Disorder Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Dosage Form
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Italy Retinal Disorder Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Dosage Form
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. France Retinal Disorder Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Dosage Form
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Retinal Disorder Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Dosage Form
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Retinal Disorder Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Dosage Form
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Retinal Disorder Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Dosage Form
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Retinal Disorder Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Dosage Form
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Retinal Disorder Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Dosage Form
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Retinal Disorder Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Dosage Form
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Retinal Disorder Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Dosage Form
      • 8.3.5.2.3. By Distribution Channel

9. South America Retinal Disorder Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Dosage Form
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Retinal Disorder Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Dosage Form
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Retinal Disorder Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Dosage Form
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Retinal Disorder Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Dosage Form
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Retinal Disorder Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Dosage Form
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Retinal Disorder Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Dosage Form
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Retinal Disorder Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Dosage Form
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Retinal Disorder Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Dosage Form
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Retinal Disorder Treatment Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Santen Pharmaceutical Co., Ltd.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Regeneron Pharmaceuticals Inc.
• 14.3. Graybug Vision, Inc.
• 14.4. Shire plc (Takeda Pharmaceutical Company Limited)
• 14.5. Bayer AG
• 14.6. AbbVie Inc.
• 14.7. Genentech (F. Hoffmann-La Roche Ltd)
• 14.8. Kubota Vision Inc.
• 14.9. Pfizer, Inc.
• 14.10.Bausch + Lomb

15. Strategic Recommendations

16. About Us & Disclaimer